A Randomized Double-Blind Placebo-Controlled Phase III Trial of Selegiline Monotherapy for Early Parkinson Disease.

Clin Neuropharmacol · 2017 · PMC5610558 · PMID 28857772

Europe PMC DOI

hedged sentence

0.2310

closest p · 4.6× alpha

0.2310

boldest claim

The sentences

did not reach statistical significanceP = 0.231not close (p > 0.1)

Use of selegiline without levodopa did not reach statistical significance (27.5% vs 18.8%, P = 0.231, n = 69 vs 64).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.